Related references
Note: Only part of the references are listed.Aspirin Use and Reduced Risk of Pancreatic Cancer
Harvey A. Risch et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk
James R. Davenport et al.
MOLECULAR CARCINOGENESIS (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women's Health Study
Lisa E. Vaughan et al.
CANCER CAUSES & CONTROL (2016)
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study
Pik Fang Kho et al.
CANCER CAUSES & CONTROL (2016)
Cohort Profile: The Shanghai Men's Health Study
Xiao-Ou Shu et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2015)
Case-Control Study of Aspirin Use and Risk of Pancreatic Cancer
Samantha A. Streicher et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Urinary Prostaglandin E2 Metabolite and Breast Cancer Risk
Yong Cui et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Pancreatic Adenocarcinoma
David P. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High-Dose Aspirin Consumption Contributes to Decreased Risk for Pancreatic Cancer in a Systematic Review and Meta-analysis
Xi-Jun Cui et al.
PANCREAS (2014)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Urinary PGE-M: A Promising Cancer Biomarker
Dingzhi Wang et al.
CANCER PREVENTION RESEARCH (2013)
Obesity and breast cancer: role of inflammation and aromatase
Evan R. Simpson et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2013)
Urinary Prostaglandin E2 Metabolite and Risk for Colorectal Adenoma
Martha J. Shrubsole et al.
CANCER PREVENTION RESEARCH (2012)
Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands
Jie Tian et al.
MOLECULAR CARCINOGENESIS (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Aspirin use and pancreatic cancer risk
Martina Bonifazi et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2010)
Urinary Prostaglandin E2 Metabolite and Gastric Cancer Risk in the Shanghai Women's Health Study
Linda M. Dong et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Aspirin, salicylates, and cancer
Peter C. Elwood et al.
LANCET (2009)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer
Hiroyuki Matsubayashi et al.
CANCER BIOLOGY & THERAPY (2007)
Inflammation and IGF-I activate the Akt pathway in breast cancer
Robyn L. Prueitt et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Urine PGE-M:: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia
J. Chad Johnson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk
Qiuyin Cai et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer
A Juuti et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
The Shanghai Women's Health Study: Rationale, study design, and baseline characteristics
W Zheng et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2005)
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay:: determination of cyclo oxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer
LJ Murphey et al.
ANALYTICAL BIOCHEMISTRY (2004)
Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters
K Merati et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
MT Yip-Schneider et al.
CARCINOGENESIS (2000)
Share Paper
